Health Canada has approved Boehringer Ingelheim‘s oral therapy Jascayd (nerandomilast) as a treatment for adults with idiopathic…
Articles by Marisa Horak, MS
Admilparant, an experimental oral therapy being developed by Bristol Myers Squibb, slowed lung function declines among people with…
Computer-based analyses of CT scans can help to predict future disease progression and track response to treatment among people with…
September is Pulmonary Fibrosis Awareness Month, and advocates around the globe are joining together to shine a light on what…
The inhaled therapy MNKD-201 was tolerated well in people with idiopathic pulmonary fibrosis (IPF) in a Phase 1 clinical…
An international clinical trial testing LTI-03, Rein Therapeutics’ inhaled treatment candidate for idiopathic pulmonary fibrosis (IPF), is now…
The oral therapy Jascayd (nerandomilast) has been approved in the European Union for adults with idiopathic pulmonary fibrosis…
The Pulmonary Fibrosis Foundation (PFF), an advocacy group dedicated to advancing care for people with pulmonary fibrosis, has…
Two Phase 3 clinical trials testing Tyvaso (treprostinil) in people with idiopathic pulmonary fibrosis (IPF) both met their…
Insilico Medicine will soon launch an early clinical trial in China to test an inhaled version of its therapy…